Prognostic significance of supradiaphragmatic lymph node metastasis detected by $^{18}$F-FDG PET/CT in advanced epithelial ovarian cancer

In Ok Lee†, Jung-Yun Lee‡, Hyun Jeong Kim, Eun Ji Nam, Sunghoon Kim, Sang Wun Kim, Chang Young Lee, Won Jun Kang* and Young Tae Kim*

Abstract

Background: Supradiaphragmatic lymph node metastases (SdLNM) are frequently identified using $^{18}$F-FDG positron emission tomography/computed tomography (PET/CT) in advanced epithelial ovarian cancers (AEOC). This study aimed to determine the prognostic significance of SdLNM detected by PET/CT in patients with AEOC.

Methods: Medical records of patients diagnosed with AEOC were retrospectively registered from January 2009 to July 2015. Patients were categorized according to PET/CT stage: PET/CT stage III, PET/CT stage IV with SdLNM, and PET/CT stage IV with other metastases. Clinicopathologic characteristics, recurrence patterns, survival outcomes were compared according to PET/CT stage. Anatomical distribution of SdLNM and effect of thoracic debulking surgery were estimated.

Results: A total of 295 patients were identified, including 176 patients who underwent primary debulking surgeries (PDS). Progression-free ($P = 0.671$) and overall ($P = 0.525$) survival did not differ significantly between patients with PET/CT IV with SdLNM and PET/CT IV with other metastases; however, patients with PET/CT IV with SdLNM had significantly poorer progression-free ($P < 0.001$) and overall ($P = 0.016$) survival than those with PET/CT stage III. Recurrence patterns were similar in all groups; intraperitoneal metastasis was the most common (78.8%) and thoracic recurrence alone accounted for less than 10%. Debunking of SdLNM lesions did not improve progression-free survival ($P = 0.425$) or overall survival ($P = 0.465$) of patients with AEOC.

Conclusions: SdLNM detected using preoperative PET/CT are a negative prognostic factor in AEOC. Resection of suspicious SdLNM may not have effect to survival of patients with AEOC.

Keywords: Ovarian cancer, Ovarian neoplasm, Supradiaphragmatic lymph node, PET/CT, Survival, Recurrence pattern

Background

Complete tumor resection is important in patients with advanced epithelial ovarian cancer (AEOC). Although optimal debulking surgery leaving $< 1$ cm of residual tumor is known to improve the overall survival of patients with AEOC [1, 2], complete debulking surgery leaving no macroscopic disease can maximize the survival benefit [3, 4]. Most studies describing optimal or no gross residual disease have only evaluated intraperitoneal disease; only a few studies have examined extraperitoneal disease so far.

After introducing of $^{18}$F-FDG positron emission tomography/computed tomography (PET/CT) scanning for preoperative evaluation, extraperitoneal disease has raised further questions about management of AEOC. PET/CT could better discriminate malignancy from benign ovarian tumor, compared to other preoperative...
imaging modalities such as ultrasonography, abdominopelvic computed tomography (CT) or magnetic resonance image (MRI) [5]. Distant metastases including nodal involvement could be predicted more accurately by preoperative PET/CT than CT [6]. Nonetheless in an era of extensive preoperative imaging modalities, management of AEOC with supradiaphragmatic lymph node metastasis (SdLN) following an initial PET/CT remains uncertain [7].

The prognosis of pathologically confirmed SdLN has not been clarified for AEOC. There has been little research of the prognostic impact of SdLN in AEOC. Fruscio et al. found that PET/CT led to an upstaging of about one fourth of ovarian cancer patients from stage III to IV after SdLN detection [8]; however, they concluded that the prognosis of patients with stage IV metastases detected by PET/CT was similar to that of those at stage IIIC. In another study, recurrence pattern of stage IV ovarian cancer patients was evaluated to determine the benefit of thoracic cytoreduction [9]; however, since thorax-only recurrence was very rare, the authors assumed that thoracic debulking would not change the course of stage IV ovarian cancer. None of the previous studies reported any association between surgical resection and pathology of SdLN detected using PET/CT. Therefore, this study aimed to determine the prognostic significance of SdLN detected using PET/CT in patients with AEOC.

Methods
Study population
We retrospectively reviewed the medical records of patients diagnosed with ovarian cancer after surgical management of pelvic mass or peritoneal disease, between January 2009 and July 2015. Patients with available preoperative PET/CT scan images, at stage IIIB to IVB after SdLN detection [8]; however, they concluded that the prognosis of patients with stage IV metastases detected by PET/CT was similar to that of those at stage IIIC. In another study, recurrence pattern of stage IV ovarian cancer patients was evaluated to determine the benefit of thoracic cytoreduction [9]; however, since thorax-only recurrence was very rare, the authors assumed that thoracic debulking would not change the course of stage IV ovarian cancer. None of the previous studies reported any association between surgical resection and pathology of SdLN detected using PET/CT. Therefore, this study aimed to determine the prognostic significance of SdLN detected using PET/CT in patients with AEOC.

PET/CT technique
Patients were instructed to fast for over 8 h before PET image acquisition. Blood glucose concentrations were confirmed to be lower than 140 mg/dL; 5.5 MBq of $^{18}$F-FDG per kg body weight was injected intravenously, with patients lying comfortably for an uptake period of 60 min. Integrated FDG-PET/CT was performed using a dedicated PET/CT scanner (Discovery STE; GE Healthcare, Milwaukee, WI). Unenhanced CT scan was performed from the vertex of the skull to the mid-thigh using the following parameters: 120 kVp, 30 mA, 0.8-s rotation time, 3.75 mm helical thickness, 27 mm per rotation (speed), 2.5 mm scan reconstruction, with a reconstruction index of 1.25 mm, 15.7 cm field of view, and a 512 × 512 matrix. A PET scan was then acquired from the cerebellum to the proximal thigh with an acquisition time of 3 min per bed position in the three-dimensional mode. PET data were reconstructed iteratively using an ordered-subset expectation maximization algorithm.
**Image analysis**

All $^{18}$F-FDG PET/CT images were independently reviewed visually by two nuclear medicine physicians. One nuclear medicine physician has 15 years of expertise and the other has 7 years of it. Each region with $^{18}$F-FDG uptake higher than the background was considered significant after exclusion of physiologic uptake. For the quantitative analysis, the maximum standardized uptake (SUVmax) values were measured by drawing a circular region of interest (ROI) at the site of the maximum $^{18}$F-FDG uptake on transaxial PET images. The SUVmax of the ROI was calculated as follows: $[\text{decay-corrected activity (MBq) per tissue volume (mL)}]/ [\text{injected } ^{18}\text{F-FDG dose (MBq) per body mass (g)}]$. The sizes of the SdLNs were measured on CT images and recorded for data analysis.

The SdLNs consisted of five subdivisions. The lymph nodes in the anterior mediastinal space were divided into two groups: cardiophrenic lymph nodes (CPLN) in the lower space and parasternal lymph nodes in the upper space (Fig. 1a). Medial and posterior mediastinal lymph nodes were counted as one group. In addition, dimensions of the SCFLN, and AxLN and their SUVmax were measured.

**Statistical analysis**

To compare groups, a two-tailed Student t-test and Fischer’s exact test were used. Kaplan-Meier estimates and log-rank tests were performed to analyze survival. Hazard ratios (HRs) for survival were estimated with a Cox proportional hazards model. SPSS version 23.0 (IBM Corp, Armonk, NY, U.S.A.) was used to analyze the data.

**Results**

From January 2009 to July 2015, 576 patients underwent surgery for and were diagnosed with primary epithelial ovarian cancer at our institution (Fig. 1b). Among them, 336 patients had staged IIIb to IVb primary epithelial ovarian cancer. Patients who did not undergo initial PET/CT evaluations were excluded. Finally, data from 295 patients were analyzed, of which 176 patients underwent PDS and 119 patients underwent NAC followed by IDS. Among the patients who underwent PDS, 108 (55.9%) belonged to the PET/CT III group. Forty patients (24.4%) had only showed SdLNM on preoperative PET/CT scans, and 28 patients (19.7%) showed evident involvement of other organ on the PET/CT scans. No statistically significant difference was noted in preoperative serum CA-125 levels among the groups ($p = 0.13$). Similarly,
other clinicopathologic characteristics including residual disease after PDS ($p = 0.405$) were not significantly different among the three groups (Table 1).

Among the patients with PDS, 50 (28.4%) had $^{18}$F-FDG uptake in the SdLNs on preoperative PET/CT. The most-frequent SdLNM detected by PET/CT was observed in the SCFLN (42%) (Table 2). Median size of SdLNM was 7.65 mm. There were 27 patients (54.0%) who underwent resection of thoracic lesions for SdLNM identification, of which two patients underwent only fine-needle biopsy for suspicious SCFLN to confirm metastasis. For the remaining 25 patients, a surgeon from Department of Chest Surgery performed either VATS or thorough excision of lesions during their PDS. Among the 25 patients who underwent thoracic debulking surgery, 21 patients (77.8%) presented with pathologic SdLNM and four patients had only inflammatory changes.

Of the entire study cohort, including the NAC and PDS groups, 151 patients (51.2%) experienced recurrence. Intraperitoneal recurrence was the most-common type of recurrence (78.8%), and <10% of the patients showed recurrence in thoracic space only (Table 3). The recurrence patterns were similar among the three groups, regardless of imaging stage. Three of the patients who experienced recurrence only in thoracic space died (overall survival rate 72.7%); on the other hand, 43 patients who experienced recurrence only in the intraperitoneal space died (overall survival rate 63.2%). However, the survival outcomes did not show a statistical significance ($p = 0.634$).

Both progression-free ($P = 0.671$) and overall ($P = 0.525$) survival did not differ significantly between patients with PET/CT IV with SdLNM and those with PET/CT IV with other metastases; however, those with PET/CT IV with SdLNM had significantly poorer progression-free (median PFS: 14 months, $P < 0.001$) and overall (median OS: 31.5 months $P = 0.016$) survival than those with PET/CT stage III (median PFS: 18 months, median OS: 37.5 months) (Fig. 2). Patients who had thoracic debulking surgery during PDS did not show a progression-free-survival ($P = 0.425$) or overall survival ($P = 0.465$) benefit compared to patients who did not undergo a supradiaphragmatic debulking procedure (Fig. 3).

There were 8 patients who had only CPLN metastases without other extraperitoneal metastases in PET/CT, and 42 patients had SdLNM. Although the group of the patients with CPLN metastases only experienced lower rate of recurrence and death, PFS and OS of the group did not show statistical differences ($p = 0.225$, 0.566, respectively) (Fig. 4) compared to the group of the patients having SdLNM.

### Table 1 Patient characteristics

|                        | total n | %         | PET_CT stage III (n, %) | PET_CT stage IV by SdLNM (n, %) | PET_CT stage IV by other (n, %) | $p$-value |
|------------------------|---------|-----------|-------------------------|---------------------------------|---------------------------------|-----------|
| median Age (years, IQR)| 176     | 100       | 108                     | 55.9                            | 40                              | 22.4      |
|                        |         |           |                         | 28                              | 19.7                            |           |
| median initial CA-125 (U/mL, IQR)| 848.05 (334.97–2387.32) | 659.35 (296.20–2446.90) | 1111.80 (712.0–2483.15) | 1048.15 (1484.45–2111.65) | 0.130 |
| FIGO stage             |         |           |                         |                                 |                                 |           |
| IIIB                   | 11      | 6.3       | 8                       | 7.4                             | 3                               | 7.5       |
|                        |         |           |                         |                                 |                                 | 0         |
| IIIC                   | 100     | 56.8      | 76                      | 70.4                            | 13                              | 32.5      |
|                        |         |           |                         |                                 |                                 | 11        |
| IVA                    | 4       | 2.3       | 3                       | 2.8                             | 1                               | 2.5       |
|                        |         |           |                         |                                 |                                 | 0         |
| IVB                    | 61      | 34.7      | 21                      | 19.4                            | 23                              | 57.5      |
|                        |         |           |                         |                                 |                                 | 17        |
| Histology              |         |           |                         |                                 |                                 | 60.7      |
|                        |         |           |                         |                                 |                                 | 0.502     |
| high grade serous     | 136     | 77.3      | 82                      | 75.9                            | 34                              | 85.0      |
|                        |         |           |                         |                                 |                                 | 20        |
| others                 | 40      | 22.7      | 26                      | 24.1                            | 6                               | 15.0      |
|                        |         |           |                         |                                 |                                 | 8         |
| Grade                  |         |           |                         |                                 |                                 | 28.6      |
|                        |         |           |                         |                                 |                                 | 0.423     |
| 1                      | 14      | 8.0       | 10                      | 9.3                             | 2                               | 5.0       |
|                        |         |           |                         |                                 |                                 | 2         |
| 2                      | 59      | 33.5      | 38                      | 35.2                            | 13                              | 32.5      |
|                        |         |           |                         |                                 |                                 | 8         |
| 3                      | 88      | 50.0      | 50                      | 46.3                            | 23                              | 57.5      |
|                        |         |           |                         |                                 |                                 | 15        |
| unknown                | 15      | 8.5       | 0.0                     |                                 |                                 | 0.0       |
| Residual disease (NGR vs other) |         |           |                         |                                 |                                 |           |
| NGR                    | 38      | 25.9      | 23                      | 26.1                            | 10                              | 27.8      |
|                        |         |           |                         |                                 |                                 | 5         |
| any residuals          | 109     | 74.1      | 65                      | 72.2                            | 26                              | 72.2      |
|                        |         |           |                         |                                 |                                 | 18        |
| unknown                | 29      | 20        | 4                       |                                 |                                 | 5         |

$NGR$ No gross residual disease
No residual disease after PDS (HR = 0.52, 95% CI = 0.29–0.93, p = 0.004) and initial PET/CT stage IV including both SdLNM and other metastases (HR = 1.61, 95% CI = 1.13–2.29, p = 0.008) were the main contributing factors for progression-free survival of the patients after multivariate analysis (Additional file 1: Table S1).

**Discussion**

The present study showed that SdLNM detected by preoperative PET/CT is a significant negative prognostic factor in AEOC. Patients in the PET/CT IV group with SdLNM and the PET/CT IV group with other metastases showed similar survival outcomes. Moreover, resection of suspicious lymph nodes may not have affected survival of patients with SdLNM detected by PET/CT. To the best of our knowledge, this is the first study to pathologically and surgically validate the results of PET/CT for SdLNM detection and to determine their prognostic impact in patients with AEOC.

The definition and location of the SdLN has been confused when describing metastatic disease. These lymph nodes, located beneath the sternum and immediately above the heart, have been named differently as paracardiac, cardiophrenic, or supradiaphragmatic lymph nodes, depending on the study [11–13]. The former two lymph nodes are actually chest wall (parietal) lymph nodes, which are not usually involved in lung or heart diseases that consist of major thoracic organ problem [14]. The chest wall lymph nodes are believed to be afferents of whole abdominal cavity circulation [15]. Compared to CT alone, PET/CTs increase the probability of SdLNM discovery during preoperative imaging. The advantage of whole-body PET/CT is that it allows a surgeon to discover suspicious extra- and intra-peritoneal metastases. Farmakis et al. found that PET/CT was more accurate than CT alone for identifying CPLNs [16]. Similarly, Fruscio et al. also concluded that PET/CT was a better methodology than CT for detecting distant metastases in AEOC [8]: PET/CT accurately upstaged 26% of the patients from FIGO stage III to IV during preoperative PET/CT imaging. In addition, Hynninen et al. reported that preoperative PET/CT detected SdLNM in 67% of patients with advanced ovarian cancer, which is almost double the detection rate with CT alone [17].

Suspicious supradiaphragmatic lymph nodes on preoperative image have been regarded as a negative predictor of AEOC. Holloway et al. reported a relationship between the extent of peritoneal metastasis and enlargement of the paracardiac lymph nodes [11]. Kolev et al. investigated supradiaphragmatic lymphadenopathy detected on preoperative CT in patients with primary ovarian cancer and found that patient survival decreases with SdLN enlargement [12]. Raban et al. showed similar results for the treatment of stage IIIC ovarian cancer: Patients showing paracardiac lymph node enlargement on preoperative CT scans had poorer outcomes than those without chest lesions [18].

Notably, none of the previous studies reported a correlation between pathologically identified SdLNM, which

| SdLNM location                        | n  | %  | median size (mm, range) | median SUVmax (range) | pathologic confirmed metastasis (N of pathologic positive /N of excision or biopsy done) |
|---------------------------------------|----|----|-------------------------|-----------------------|----------------------------------------------------------------------------------|
| Cardiophrenic                          | 15 | 30.0 | 7.65 (3.9–13.0)         | 2.6 (1.4–14.1)        | 8/10                                                                             |
| Parasternal                            | 15 | 30.0 | 6.6 (4.9–15.7)          | 2.4 (1.2–10.7)        | 7/8                                                                              |
| middle/posterior mediastinal           | 7  | 14.0 | 10 (3.5–17.6)           | 4.2 (2.3–9.4)         | 1/2                                                                              |
| Axillary                               | 10 | 20.0 | 9 (4.4–19.3)            | 2.6 (1.1–8.1)         | 3/3                                                                              |
| Supraclavicular or Neck node           | 21 | 42.0 | 9.1 (3.5–24.9)          | 3.2 (1.2–14.7)        | 5/6                                                                              |

**Table 2** Incidence of supradiaphragmatic lymph node metastases (SdLNM) in PDS group

| Total PET_CT stage III | PET_CT stage IV by SdLNM | PET_CT stage IV by other |
|------------------------|--------------------------|--------------------------|
| Numbers of recurrence  | 151                      | 75                       | 41                       |
| Recurrent rate (%)     | 51.2                     | 45.5                     | 56.9                     |
| Location of recurrence | N                        | %                        | N                        |
| Thoracic space         | 11                       | 7.3                      | 6                        |
| Intraperitoneal space  | 119                      | 78.8                     | 60                       |
| Thoracic + Intraperitoneal space | 12 | 7.9          | 5                        |
| Pleural effusion only  | 5                        | 3.3                      | 2                        |
| other (brain, bone, skin) | 3                         | 2.0                      | 1                        |
| unknown (f/u loss)     | 1                        | 0.7                      | 1                        |

**Table 3** Recurrence pattern depends on primary disease extent by PET_CT
was first detected by PET/CT, and its prognostic significance. Some studies on the detection of SdLNMs by preoperative imaging demonstrated that presence of chest lymph node lesions correlated with a poorer prognosis in patients with AEOC [11, 12, 18]. However, one study showed that in cases where PET/CT indicated stage IV disease that was otherwise image stage III by other imaging modalities, the survival of the both groups would be similar [8]. In our study, we performed either node excision or biopsy for 54% of the patients showing SdLNMs on PET/CT, which pathologically confirmed metastases. Based on our data, patients with SdLNMs only on preoperative PET/CT had worse outcome than those with PET/CT stage III and had a similar progression-free-survival rate as compared to those with PET/CT stage IV with other metastases.

Several procedures were introduced for SdLNMs removal in AEOC. VATS has been evaluated as a diagnostic tool for intra-thoracic disease, and is feasible for removal of suspicious lesions in AEOC [19, 20]. In addition, trans-diaphragmatic CPLN dissection also was recently introduced as a feasible procedure that does not require the assistance of a thoracic surgeon [21, 22]. However, based on our study data, progression-free-survival of the patients who underwent the supradiaphragmatic procedure during the PDS was not significantly different from that of

![Graphs](image1.png)

**Fig. 2** Kaplan-Meier curves of progression-free survival (a) and overall survival (b) according to PET/CT stages

![Graphs](image2.png)

**Fig. 3** Kaplan-Meier curves of progression-free survival (a) and overall survival (b) according to thoracic debulking
patients who did not undergo the procedure. In this study, we did not observe a survival benefit for SdLNM resection because of the small numbers of patients who underwent thoracic debulking.

The recurrence pattern in patients with PET/CT stage IV patients could be another factors reasonable for the small benefit of SdLNM removal. Peri et al. reported on the recurrence of stage IV ovarian cancer patients [9]. Similarly, in this study, the recurrence pattern of PET/CT stage IV ovarian cancer was similar to that of PET/CT stage IIIC cancer. Recurrence occurred most frequently in the intra-peritoneal space, and < 10% of the cohort demonstrated thoracic recurrence only. These data may be further evidence to support the fact that supradiaphragmatic procedures confer little benefit to patients with the PET/CT IV with SdLNM.

Our study and other studies question the importance of SdLNM location in AEOC. Previous studies suggested that the anterior chest wall lymph nodes are the major site of SdLNM [8]; however, in this study, SCFLN metastases were the most-prevalent SdLNM identified on PET/CT. It is currently unclear whether SdLNs should be categorized according to their origin of drainage. Hynninen reported [17] that if there are two different lymphatic pathways from the peritoneal cavity to the thoracic cavity, the anterior chest wall lymph node metastases would correlate with PET/CT stage III patients. CPLN might be a thoracic marker of extensive peritoneal stage III disease. Thus, SCFLNs drained from deep pelvic lymph node chains might have a different prognostic impact than CPLN. A redefinition of SdLNM based on location and lymphatic afferents may impact our understanding of residual disease after debulking surgery in AEOC.

Despite our important findings, this study had a limitation. Owing to its retrospective design, there may have been a selection. However, we attempt to recruit a homogenous patient cohort in order to analyze progression-free survival data of patients who underwent PDS. The strength of our study is that SdLNM detected by PET/CT was pathologically confirmed. However, the extent of thoracic debulking varied in this study, which could have affected the progression-free-survival of patients who underwent the supradiaphragmatic procedure.

Conclusions

Patients with AEOC in whom SdLNM was detected using preoperative PET/CT had a poorer prognosis than those without SdLNM and those with other distant metastases. Removal of SdLN lesions may not affect the survival of patients with AEOC. However, further investigation is warranted to determine whether there are location-dependent survival effects of SdLNM in patients with AEOC.

Additional file

Additional file 1: Table S1. Hazard ratio for recurrence and overall survival. (DOCX 15 kb)

Abbreviations

AEOC: Advanced epithelial ovarian cancer; CT: Computed tomography; MRI: Magnetic resonance image; PET/CT: Positron emission tomography/ computed tomography; SdLN: Supradiaphragmatic lymph nodes; SdLNM: Supradiaphragmatic lymph node metastasis; FIGO: International Federation of Gynecology and Obstetrics; NAC: Neoadjuvant chemotherapy;
IDS: Interval debulking surgery; PDS: Primary debulking surgery; VATS: Video-assisted thoracoscopic surgery; SCFLN: Supravclavicular fossa lymph node; AxLN: Axillary lymph nodes; CPNL: Cardiophrenic lymph nodes

Acknowledgements
Not applicable.

Funding
There was no funding for this study.

Availability of data and materials
All data generated or analyzed during this study are included in this article.

Authors’ contributions
IOL, JYL, WJK and YTK were responsible for the study design. IOL, JYL, HJK, EJN, SK, SWK, CYL, WJK and YTK participated in data collection. IOL and JYL analyzed the data. IOL, JYL, WJK and YTK were involved in the interpretation of the data. IOL drafted the manuscript. IOL, JYL and YTK revised the manuscript. All authors critically read the drafts of this paper and approved its final version.

Ethics approval and consent to participate
This study was approved by the institutional review board of Yonsei University College of Medicine, which waived the requirement for informed consent based on the study design.

Consent for publication
Not applicable.

Competing interests
All authors have no competing interests to declare.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Obstetrics and Gynecology, National Health Insurance Service Ilsan Hospital, Goyang-si, Gyeonggi-do, South Korea. 2Department of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, South Korea. 3Department of Nuclear Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, South Korea. 4Department of Chest Surgery, Yonsei University College of Medicine, Seoul, South Korea.

Received: 12 June 2018 Accepted: 7 November 2018
Published online: 26 November 2018

References
1. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011(8):CD007565.
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). In Network NCC, editor. Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer; 2016.
3. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31.
4. Chang S-J, Bristow RE, Chi DS, Cliby WA. Role of aggressive surgical cytoreduction in advanced ovarian cancer. J Gynecol Oncol. 2015;26(4):336–42.
5. Nam EJ, Yun MJ, Oh YT, et al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol. 2010;116(3):389–94.
6. Castellucci P, Perrone AM, Picchio M, et al. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transluminal ultrasonography, computed tomography, and histology. Nucl Med Commun. 2007;28(8):589–95.
7. Fotopoulou C. Cytoreductive surgery: abdominal retroperitoneum and adrenopan. In: Bristow RE, Karlan BY, Chi DS, editors. SURGERY for OVARIAN CANCER. Third ed. Boca Raton, FL: CRC Press; 2015. p. 207.
8. Fruscio R, Sina F, Dolicé C, et al. Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer. Gynecol Oncol. 2013;131(3):889–93.
9. Perri T, Ben-Baruch G, Kalfon S, et al. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction? Gynecol Oncol. 2013;131(1):27–31.
10. Fagotti A, Ferrandina G, Fanfani F, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol. 2008;199:642–6 e1–e6.
11. Holloway BJ, Gore ME, AHern RP, Parsons C. The significance of paracardiac lymph node enlargement in ovarian cancer. Clin Radiol. 1997;52(9):692–7.
12. Kolm V, Mironov S, Mironov O, et al. Prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(6):974–84.
13. Kim TH, Lim MC, Kim SI, Seo SS, Kim SH, Park SY. Preoperative prediction of Cardiophrenic lymph node metastasis in advanced ovarian Cancer using computed tomography. Ann Surg Oncol. 2016;23(4):1302–8.
14. Mountain CF, Drexler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111(6):1718–23.
15. Rouvier H. Anatomie des lymphatics de l’Homme. Paris: Masson; 1935.
16. Faramakis S, Vegdanis K, Muzzaffar R, Parkar N, Orman MM. Detection of metastatic disease in Cardiophrenic lymph nodes: FDG PET/CT versus contrast-enhanced CT and implications for staging and treatment of disease. Front Oncol. 2013;3:260.
17. Hyyninen J, Auranen A, Carpen O, et al. FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread. Gynecol Oncol. 2012;126(1):64–8.
18. Raban O, Peled Y, Krissi H, et al. The significance of paracardiac lymph-node enlargement in patients with newly diagnosed stage IIIC ovarian cancer. Gynecol Oncol. 2015;138(2):259–62.
19. Juretzka MM, Abu-Rustum NR, Sonoda Y, et al. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecol Oncol. 2007;104(3):670–4.
20. Lim MC, Lee HS, Jung DC, Choi JY, Seo SS, Park SY. Pathological diagnosis and cytoreduction of cardiophrenic lymph node and pleural metastasis in ovarian cancer patients using video-assisted thoracic surgery. Ann Surg Oncol. 2009;16(7):1990–6.
21. Yoo HJ, Lim MC, Song YJ, et al. Transabdominal cardiophrenic lymph node dissection (CPNL) via incised diaphragm replace conventional video-assisted thoracic surgery for cytoreductive surgery in advanced ovarian cancer. Gynecol Oncol. 2013;129(2):341–5.
22. Prader S, Harter P, Grimm C, et al. Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer. Gynecol Oncol. 2016;141(2):271–5.